Shattuck Labs FY2024 EPS Forecast Decreased by HC Wainwright

Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) - Stock analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Shattuck Labs in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($1.54) per share for the year, down from their previous forecast of ($1.41). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Shattuck Labs' current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Shattuck Labs' Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

Several other research firms also recently issued reports on STTK. Citigroup downgraded shares of Shattuck Labs from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $8.00 to $2.00 in a report on Wednesday, October 2nd. Evercore ISI upgraded Shattuck Labs to a "strong-buy" rating in a research report on Wednesday, October 2nd. Finally, Needham & Company LLC restated a "hold" rating on shares of Shattuck Labs in a report on Thursday. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $8.67.

Shattuck Labs Stock Down 10.5 %

Shares of Shattuck Labs stock traded down $0.13 on Monday, reaching $1.11. The company's stock had a trading volume of 351,340 shares, compared to its average volume of 450,500. Shattuck Labs has a 52-week low of $1.07 and a 52-week high of $11.76. The company has a market capitalization of $52.74 million, a P/E ratio of -0.72 and a beta of 1.85. The stock has a 50-day moving average price of $2.03 and a 200-day moving average price of $4.12.

Hedge Funds Weigh In On Shattuck Labs

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Shattuck Labs by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company's stock valued at $3,184,000 after purchasing an additional 8,133 shares during the last quarter. Barclays PLC boosted its stake in shares of Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company's stock valued at $189,000 after buying an additional 40,717 shares during the period. EP Wealth Advisors LLC acquired a new stake in shares of Shattuck Labs in the 3rd quarter valued at $144,000. State Street Corp lifted its holdings in Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company's stock worth $2,675,000 after buying an additional 55,579 shares during the last quarter. Finally, Readystate Asset Management LP purchased a new position in Shattuck Labs in the third quarter valued at approximately $39,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Taylor Schreiber purchased 36,500 shares of the stock in a transaction dated Monday, October 7th. The shares were purchased at an average price of $1.21 per share, with a total value of $44,165.00. Following the transaction, the chief executive officer now owns 71,002 shares in the company, valued at $85,912.42. The trade was a 105.79 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.